Generic ribavirin product launched in the United States

Schering-Plough Corporation has announced that its wholly owned subsidiary Warrick Pharmaceuticals has launched a generic ribavirin product in the United States.

Schering-Plough had previously entered into a licensing agreement with Three Rivers Pharmaceuticals, LLC regarding Schering-Plough's U.S. ribavirin patents. Under terms of the agreement and as a result of launching Warrick ribavirin, Schering-Plough will not receive a royalty from Three Rivers on sales of Three Rivers' generic ribavirin product. Financial terms of the licensing agreement have not been disclosed.

Schering-Plough noted that the market for generic pharmaceutical products is volatile, particularly at launch, and it will price its generic ribavirin product according to market conditions and applicable regulations.

Schering-Plough markets ribavirin, USP capsules under the brand name REBETOL(R). As previously reported, Schering-Plough expected generic competition for REBETOL in the U.S. market in 2004.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Resveratrol shows potential as SARS-CoV-2 antiviral, study finds